ESR1 and breast carcinoma: Tamoxifen (TAM) is a widely prescribed antiestrogen for the control of estrogen receptor (ER)-positive breast cancer, yet its efficacy is reduced due to the development of endocrine resistance and intrinsic patient characteristics that prevent drug response.